Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women

被引:43
|
作者
Min, SS
Corbett, AH
Rezk, N
Cu-Uvin, S
Fiscus, SA
Petch, L
Cohen, MS
Kashuba, ADM
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[5] Brown Univ, Sch Med, Providence, RI 02912 USA
关键词
female genital tract; pharmacokinetic; antiretroviral concentration; HIV-1; protease inhibitor; nonnucleoside reverse transcriptase inhibitor;
D O I
10.1097/00126334-200412150-00008
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The pharmacokinetics of antiretrovirals (ARVs) in the female genital tract (FGT) are likely to influence vertical and sexual transmission of HIV, the development of viral resistance, and post-exposure prophylaxis regimens. This study is the first to compare ARV concentrations in direct aspirates of cervicovaginal fluid (CVF) and blood plasma (BP). This unique method provides direct assessment of concentrations without the confounding of cervicovaginal lavage dilution. Of 8 ARVs, CVF concentrations ranged from <10% to >100% of BP concentrations. These large differences in CVF penetration suggest that further research into ARV pharmacokinetics and drug efficacy in the FGT is necessary.
引用
收藏
页码:1577 / 1580
页数:4
相关论文
共 50 条
  • [1] Prevalence and persistence of nonnucleoside reverse transcriptase inhibitor mutations in the female genital tract
    Newstein, M
    Losikoff, P
    Caliendo, A
    Ingersoll, J
    Kurpewski, J
    Hanley, D
    Cerezo, J
    Ramratnam, B
    Cu-Uvin, S
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (03) : 364 - 366
  • [2] Nonnucleoside Reverse Transcriptase Inhibitor Pharmacokinetics in a Large Unselected Cohort of HIV-Infected Women
    Gandhi, Monica
    Benet, Leslie Z.
    Bacchetti, Peter
    Kalinowski, Ann
    Anastos, Kathryn
    Wolfe, Alan R.
    Young, Mary
    Cohen, Mardge
    Minkoff, Howard
    Gange, Stephen J.
    Greenblatt, Ruth M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 50 (05) : 482 - 491
  • [3] Burden of Nonnucleoside Reverse Transcriptase Inhibitor Resistance in HIV-1-Infected Patients: A Systematic Review and Meta-Analysis
    Snedecor, Sonya J.
    Sudharshan, Lavanya
    Nedrow, Katherine
    Bhanegaonkar, Abhijeet
    Simpson, Kit N.
    Haider, Seema
    Chambers, Richard
    Craig, Charles
    Stephens, Jennifer
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (08) : 753 - 768
  • [4] Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients
    Marcelin, Anne-Genevieve
    Flandre, Philippe
    Descamps, Diane
    Morand-Joubert, Laurence
    Charpentier, Charlotte
    Izopet, Jacques
    Trabaud, Mary-Anne
    Saoudin, Henia
    Delaugerre, Constance
    Tamalet, Catherine
    Cottalorda, Jacqueline
    Bouvier-Alias, Magali
    Bettinger, Dominique
    Dos Santos, Georges
    Ruffault, Annick
    Alloui, Chakib
    Henquell, Cecile
    Rogez, Sylvie
    Barin, Francis
    Signori-Schmuck, Anne
    Vallet, Sophie
    Masquelier, Bernard
    Calvez, Vincent
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (01) : 72 - 77
  • [5] High nonnucleoside reverse transcriptase inhibitor resistance levels in HIV-1-infected Zambian mother-infant pairs
    Bennett, Sydney J.
    Chunda-Liyoka, Catherine
    Poppe, Lisa K.
    Meinders, Katie
    Chileshe, Chisanga
    West, John T.
    Wood, Charles
    AIDS, 2020, 34 (12) : 1833 - 1842
  • [6] The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults
    Mackie, Nicola E.
    Dunn, David T.
    Dolling, David
    Garvey, Lucy
    Harrison, Linda
    Fearnhill, Esther
    Tilston, Peter
    Sabin, Caroline
    Geretti, Anna M.
    AIDS, 2013, 27 (14) : 2245 - 2253
  • [7] Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor plus protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor plus nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial
    Soulie, Cathia
    Assoumou, Lambert
    Ghosn, Jade
    Duvivier, Claudine
    Peytavin, Gilles
    Ait-Arkoub, Zaina
    Molina, Jean-Michel
    Costagliola, Dominique
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    AIDS, 2009, 23 (12) : 1605 - 1608
  • [8] Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans
    Nanzigu, S.
    Eriksen, J.
    Makumbi, F.
    Lanke, S.
    Mahindi, M.
    Kiguba, R.
    Beck, O.
    Ma, Q.
    Morse, G. D.
    Gustafsson, L. L.
    Waako, P.
    HIV MEDICINE, 2012, 13 (04) : 193 - 201
  • [9] Evolution of protease and reverse transcriptase inhibitor resistance-associated mutations in HIV-1-infected protease inhibitor-treated patients with persistent low viraemia
    Duval, X
    Descamps, D
    Breton, G
    Darmon, S
    Ecobichon, JL
    Delarue, S
    Peytavin, G
    Leport, C
    Vildé, JL
    Brun-Vézinet, F
    ANTIVIRAL THERAPY, 2005, 10 (01) : 197 - 199
  • [10] Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding
    Sluis-Cremer, N
    Temiz, NA
    Bahar, I
    CURRENT HIV RESEARCH, 2004, 2 (04) : 323 - 332